Bio-Rad Laboratories (BIO) AI Stock Analysis

• Market Cap: $7.59B
• Dividend Yield: N/A
• Average Volume (3M): 224.45K
• Price to Earnings (P/E): 24.4
• Beta (1Y): 0.76
• Revenue Growth: -0.33%
• EPS Growth: N/A
• Country: US
• Employees: 7,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 2.61
• Shares Outstanding: 21,992,308
• 10 Day Avg. Volume: 217,119
• 30 Day Avg. Volume: 224,452
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: 2.58
• Enterprise Value/Gross Profit: 4.89
• Enterprise Value/Ebitda: 9.62
• 1Y Price Target: $342.33
• Price Target Upside: 22.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 69 Neutral
• Price Target: $313.00 ▲(11.67% Upside)

Bio-Rad Laboratories' overall score is driven by its strong financial foundation and positive technical indicators. The company's strategic focus and recent acquisitions support future growth, despite challenges in certain market segments and valuation concerns.

Positive Factors

Strong Balance Sheet

Bio-Rad's low leverage and strong equity base provide financial stability and flexibility, supporting long-term strategic investments and resilience against economic fluctuations.

Product Portfolio Expansion

The acquisition and new product launches enhance Bio-Rad's competitive position in the digital PCR market, driving future revenue growth and market share expansion.

Improved Cash Flow

Rising free cash flow indicates efficient operations and strong cash generation, enabling Bio-Rad to fund growth initiatives and maintain financial health.

Negative Factors

Decline in Diagnostics Sales

Stagnant diagnostics sales could hinder revenue growth and profitability, necessitating strategic adjustments to regain momentum in this key segment.

Lower Gross Margin

Decreasing gross margins, driven by higher material costs, could pressure profitability, requiring cost management and pricing strategies to sustain margins.

Market Softness in Biotech

Weak demand in biotech and academic sectors may limit growth opportunities, necessitating diversification and innovation to capture new market segments.

Bio-Rad Laboratories Business Overview & Revenue Model

Company Description

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

How the Company Makes Money

Bio-Rad generates revenue through the sale of a diverse portfolio of products primarily in the life sciences and clinical diagnostics markets. The Life Science segment contributes significantly to revenue through the sale of reagents, instruments, and consumables utilized in research and drug development. Key revenue streams include products for protein purification, gene expression analysis, and cellular biology. In the Clinical Diagnostics segment, the company earns revenue from diagnostic tests and assays that aid in disease detection and management, including immunology, blood typing, and infectious disease testing. Additionally, Bio-Rad has established partnerships with various healthcare organizations and research institutions, which help expand its market reach and drive sales. The company also benefits from recurring revenue through consumables and maintenance contracts tied to its instruments, creating a stable income stream.

Bio-Rad Laboratories Financial Statement Overview

Summary

Bio-Rad Laboratories shows signs of recovery with improvements in profitability and cash flow generation. The company maintains a strong balance sheet with low leverage, providing a stable financial foundation. However, the company needs to focus on sustaining revenue growth and enhancing profitability to achieve industry-leading performance.

Income Statement

Bio-Rad Laboratories has shown a mixed performance in its income statement. The TTM (Trailing-Twelve-Months) data indicates a gross profit margin of 52.8%, which is healthy, but there is a significant decline in net profit margin to 12.5% from previous negative margins, indicating improvement but still below industry standards. Revenue growth has been inconsistent, with a recent positive trend of 51.6% in TTM, suggesting recovery. EBIT and EBITDA margins have improved to 19.5% and 26.9% respectively, showing better operational efficiency.

Balance Sheet

The balance sheet of Bio-Rad Laboratories reflects a stable financial position with a debt-to-equity ratio of 0.20, indicating low leverage and financial risk. The return on equity (ROE) has improved to 4.6% in TTM, recovering from negative values, but still needs enhancement. The equity ratio stands at a solid 69.8%, showcasing a strong equity base relative to total assets.

Cash Flow

Cash flow analysis reveals a positive trend with a free cash flow growth rate of 4.6% in TTM, indicating better cash generation. The operating cash flow to net income ratio is nearly 1, suggesting efficient conversion of income into cash. The free cash flow to net income ratio is 65.1%, reflecting a good level of cash flow relative to profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.55B	2.57B	2.67B	2.80B	2.92B	2.55B
Gross Profit	1.35B	1.38B	1.43B	1.57B	1.64B	1.44B
EBITDA	686.19M	-2.14B	-654.80M	-4.49B	5.59B	5.08B
Net Income	319.17M	-1.84B	-637.32M	-3.63B	4.25B	3.81B
Balance Sheet
Total Assets	10.21B	9.36B	12.30B	13.50B	17.80B	12.97B
Cash, Cash Equivalents and Short-Term Investments	1.37B	1.66B	1.61B	1.79B	869.92M	991.12M
Total Debt	1.41B	1.37B	1.41B	1.39B	223.38M	225.74M
Total Liabilities	3.09B	2.79B	3.56B	3.89B	4.11B	3.09B
Stockholders Equity	7.13B	6.57B	8.74B	9.62B	13.69B	9.88B
Cash Flow
Free Cash Flow	347.52M	266.20M	218.26M	80.29M	535.72M	476.41M
Operating Cash Flow	534.16M	455.20M	374.94M	194.45M	669.46M	584.97M
Investing Cash Flow	-198.68M	-160.20M	20.21M	-1.21B	-797.38M	-69.89M
Financing Cash Flow	-356.23M	-218.80M	-425.65M	973.58M	-55.43M	-523.04M

Bio-Rad Laboratories Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 280.29
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIO, the sentiment is Neutral. The current price of 280.29 is below the 20-day moving average (MA) of 289.06, above the 50-day MA of 273.26, and above the 200-day MA of 276.46, indicating a neutral trend. The MACD of 1.64 indicates Positive momentum. The RSI at 48.24 is Neutral, neither overbought nor oversold. The STOCH value of 20.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BIO.

Bio-Rad Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	80 Outperform	121.32B	26.11	9.73%	2.94%	4.98%	22.08%
BSX	75 Outperform	145.95B	58.46	11.16%	―	21.45%	36.19%
DXCM	73 Outperform	29.98B	53.05	22.21%	―	9.30%	-14.95%
BIO	69 Neutral	$7.59B	24.41	4.59%	―	-0.33%	―
EW	69 Neutral	44.15B	50.89	39.30%	―	-5.23%	-39.83%
PHG	56 Neutral	26.55B	-34.63	-5.85%	3.13%	-0.76%	-55.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Bio-Rad Laboratories Corporate Events

Bio-Rad Hosts Webinar on Digital PCR Advancements

On August 26, 2025, Bio-Rad Laboratories hosted an informational webinar on its Droplet Digital PCR product portfolio, highlighting the technology’s precision and scalability. The event, led by company executives, aimed to showcase Bio-Rad’s leadership in digital PCR and its potential to drive future growth by transitioning customers from traditional PCR methods to its advanced digital solutions.

The most recent analyst rating on (BIO) stock is a Buy with a $336.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.